Results 161 to 170 of about 345,409 (245)

Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions

open access: yesIbrain, EarlyView.
Alzheimer's disease treatment is evolving rapidly, with emerging strategies targeting multiple disease pathways. This graphical abstract highlights the shift from traditional therapies to innovative approaches that hold promise for improving outcomes.
Tapas Kumar Mohapatra   +4 more
wiley   +1 more source

USP37 prevents unscheduled replisome unloading through MCM complex deubiquitination. [PDF]

open access: yesNat Commun
Bolhuis DL   +7 more
europepmc   +1 more source

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner   +3 more
wiley   +1 more source

Targeting the DNA damage response through TBL1X in mantle cell lymphoma. [PDF]

open access: yesBlood Adv
Pray B   +18 more
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner   +7 more
wiley   +1 more source

CDC6 Inhibits CDK1 Activity in MII-Arrested Oocyte Cell-Free Extract. [PDF]

open access: yesInt J Mol Sci
Dillac L   +5 more
europepmc   +1 more source

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Currently, no published data on homologous recombination deficiency (HRD) testing in the setting of molecular tumor boards exist. This study in a cohort of 237 patients encompassing 24 different tumor entities assessed by a molecular tumor board shows that inactivating alterations of BRCA1/2 are not always associated with an elevated ...
Christoph Schubart   +26 more
wiley   +1 more source

Home - About - Disclaimer - Privacy